NCT07078357View on ClinicalTrials.gov

Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

December 1, 2028

Conditions
Rheumatic Heart DiseaseRheumatic Heart Disease in ChildrenVaccine Adverse ReactionRheumatic DiseasesVaccine AcceptanceVaccine
Interventions
BIOLOGICAL

StrepIncor

This arm will include 25/50/100/200 µg compared to placebo

OTHER

Placebo

A placebo (aluminum adjuvant) will be administered and compared to the other study arms

Trial Locations (1)

05403000

Heart Institute - Hospital Das Clinicas Da Faculdade de Medicina Da Universidade de São Paulo, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT07078357 - Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor | Biotech Hunter | Biotech Hunter